Cargando…

Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies

Once-daily extended-release (ER) lorazepam was developed to reduce fluctuations in plasma levels compared with lorazepam immediate-release (IR) for short-term anxiety relief. Here we report a series of phase 1 randomized, open-label, multiperiod crossover studies characterizing ER lorazepam pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathew, Sanjay J., Jean-Lys, Shedly, Phull, Rupinder, Yarasani, Rama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309101/ https://www.ncbi.nlm.nih.gov/pubmed/37335199 http://dx.doi.org/10.1097/JCP.0000000000001715

Ejemplares similares

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program
por: Andorn, Anne, et al.
Publicado: (2019)

Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults
por: Katzman, Martin A., et al.
Publicado: (2020)

LORAZEPAM FOR ALCOHOL WITHDRAWAL
por: Andrade, Chittaranjan
Publicado: (2003)

Lorazepam-induced diplopia
por: Lucca, Jisha M., et al.
Publicado: (2014)

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
por: Sambunaris, Angelo, et al.
Publicado: (2014)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

CATATONIC SYNDROME : TREATMENT RESPONSE TO LORAZEPAM
por: Payee, Haniya, et al.
Publicado: (1999)

CATATONIC SYNDROME : TREATMENT RESPONSE TO LORAZEPAM
por: Patra, Alok, et al.
Publicado: (1999)

LORAZEPAM DEPENDENCE : A CASE REPORT
por: Khanna, Sumant, et al.
Publicado: (1984)

Baclofen versus lorazepam for alcohol withdrawal
por: Garag, Sagar S., et al.
Publicado: (2019)

Lorazepam: Lack of efficacy: case report
Publicado: (2021)

Lorazepam: Lack of efficacy: case report
Publicado: (2022)

A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study
por: Fanous, Helen, et al.
Publicado: (2013)

Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder
por: Gomeni, Roberto, et al.
Publicado: (2020)

Electroconvulsive Therapy in Lorazepam Non-Responsive Catatonia
por: Girish, K., et al.
Publicado: (2003)

Adolescent Catatonia Successfully Treated with Lorazepam and Aripiprazole
por: Roberto, Aaron J., et al.
Publicado: (2014)

Anti-Intrusion Effect of Lorazepam: An Experimental Study
por: Lee, Hong-Seock, et al.
Publicado: (2013)

Role of lorazepam challenge test in childhood catatonia
por: Sharma, Chandra Madhur, et al.
Publicado: (2014)

Active Anti-Inflammatory and Hypolipidemic Derivatives of Lorazepam
por: Theodosis-Nobelos, Panagiotis, et al.
Publicado: (2019)

Haloperidol/lorazepam: Lack of efficacy: case report
Publicado: (2021)

Lorazepam: Drug abuse and dependence: case report
Publicado: (2021)

Lorazepam as a Cause of Drug-Induced Liver Injury
por: Arai, Toshio, et al.
Publicado: (2018)

Hydromorphone/lorazepam/morphine overdose: Coma: case report
Publicado: (2019)

Levetiracetam/lorazepam/phenytoin: Lack of efficacy: case report
Publicado: (2021)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2021)

Malignant catatonia responsive to low doses of lorazepam: case report: Catatonia maligna responsiva a baixas doses de lorazepam: relato de caso
por: Matias, Diego Fernando Moreira, et al.
Publicado: (2015)

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials
por: Adler, Lenard A., et al.
Publicado: (2022)

Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam
por: Yacoub, Adeeb, et al.
Publicado: (2006)

Comparison of sedation with dexmedetomidine versus lorazepam in septic ICU patients
por: Pandharipande, P, et al.
Publicado: (2008)

Lorazepam Provocation Test in Purported Schizophrenia with Lack of Treatment Response
por: Berg, John E.
Publicado: (2014)

Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome
por: Gulati, Prannay, et al.
Publicado: (2019)

The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety
por: Ching, Nathan R, et al.
Publicado: (2018)

Lorazepam induces acinar cells apoptosis of rat parotid glands
por: Bettega, Patrícia Vida Cassi, et al.
Publicado: (2020)

Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review
por: Amore, Mario, et al.
Publicado: (2021)

Antiepileptic drugs/lorazepam/propofol: Treatment failure: case report
Publicado: (2021)

Lorazepam challenge test: A unique clinical response in catatonia
por: Seetharaman, Aparna, et al.
Publicado: (2021)

Lorazepam causing drug-induced liver injury : Rare entity
por: Sellami, S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qhth0p3aadqbb9k3cf2lle5vm5